For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...
4h
ScienceAlert on MSNNew Protein Discovery Could Rival Ozempic With Fewer Side EffectsScientists have discovered a naturally-occurring molecule that aids appetite control and weight loss so well, it may compete ...
13h
Avocadu on MSNMicrodosing GLP-1s: A New Approach to Weight Loss and Metabolic HealthIf you’ve been paying attention to the weight loss world, you’ve probably heard about GLP-1 receptor agonists like Ozempic, ...
1d
News Medical on MSNGLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patientsResearchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...
GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.
4d
HealthDay on MSNNo Link Seen Between Preop GLP-1 Receptor Agonist Use and Postop Aspiration PneumoniaPreoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...
8d
News Medical on MSNNew study confirms GLP-1 medications are safe for mental health in diabetesResearchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results